

Date: 14th August, 2024

**To,
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai- 400051
NSE Symbol: VAISHALI**

Sub.: Outcome of Board Meeting held to approve Un-Audited Financial Results for the First Quarter Ended 30th June, 2024.

Dear Sir/Madam,

We wish to inform you that the Board of Directors (**'the Board'**) of the Company at their meeting held today, inter alia approved the Un-audited Financial Results for First Quarter Ended 30th June, 2024. A copy of Un-audited Financial Results for the First Quarter Ended 30th June, 2024 along with Limited Review Report on the Un-audited Financial Results pursuant to Regulation 33 and other applicable regulations of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (**'Listing Regulations'**) is enclosed herewith.

We hereby state that the statutory auditors have issued Limited Review Report for the First Quarter Ended 30th June, 2024.

The meeting of the Board commenced at 01:00 P.M. and concluded at 03:00 P.M.

Kindly take the above on record.

Thanking You,
Yours Faithfully,

For Vaishali Pharma Limited

**Atul Arvind Vasani
Managing Director**

ANNEXURE I

RAMAN S. SHAH & ASSOCIATES
CHARTERED ACCOUNTANTS

CA Raman S. Shah, B.Com ,F.C.A.
CA Santosh A. Sankhe, B.Com ,F.C.A.
CA Bharat C. Bhandari, B.Com ,F.C.A.



Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors

Vaishali Pharma Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Vaishali Pharma Limited (the "Company") for the quarter ended June 30, 2024 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and 52 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Raman S. Shah & Associates
Chartered Accountants

Firm Registration No. 119891W


Santosh A. Sankhe

Partner

Membership No. 100976

Place:- Mumbai



Date:- 14.08.2024

UDIN-24100976BKDGVQ1667

Head Office:- Sam Plaza, 'A' Wing, 2nd Floor, H.K.Irani Road, Dahanu Road (W) 401602

Branch Office:- 1) A-104, 1st Floor, Inder Darshan Building, Jamli Gali, Borivali(W), Mumbai(W), 400092
2) 118- 121, 1st Floor, "Harmony Plaza", Tarapur Road, Boisar, 401501



Valshali Pharma Ltd.

CIN - L52310MH2008PLC181632

Statement of unaudited financial results for the Quarter ended Jun 30, 2024

(₹. in Lakhs)

Sr. No.	Particulars	Quarter Ended	Quarter Ended	Quarter Ended	Year Ended
		Jun 30, 2024	Mar 31, 2024	Jun 30, 2023	Mar 31, 2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from operations	1,807.98	3,239.60	1,342.27	8,627.97
2	Other income	42.45	90.54	36.07	203.36
3	Total Income (1+2)	1,850.44	3,330.14	1,378.34	8,831.33
4	Expenditure				
	a) Purchase of Stock-in-trade	1,449.75	3,182.25	813.82	7,174.51
	b) Changes in Inventories of Finished Goods, Work-in-progress and Stock-in-trade	(0.57)	49.18	178.47	267.04
	c) Employee benefit expenses	58.68	63.14	53.93	232.38
	d) Finance cost	37.91	40.06	43.04	173.69
	e) Depreciation and amortisation expenses	11.92	14.05	11.98	50.81
	f) Other expenses (Refer Note 6)	65.72	623.10	65.19	840.29
	Total Expenses (a to f)	1,623.41	3,971.78	1,166.43	8,738.72
5	Profit before Exceptional Items and Tax	227.02	(641.64)	211.91	92.61
6	Exceptional items debit / (credit)	-	-	-	-
7	Profit before Tax	227.02	(641.64)	211.91	92.61
	Current Tax (Net) Debit / (Credit)	57.12	(169.43)	53.32	24.68
	Tax for earlier year		-	-	-
	Deferred Tax (Net) Debit / (Credit)		(3.96)	-	(3.96)
	Total Tax Expenses	57.12	(173.39)	53.32	20.72
9	Net Profit for the period	169.90	(468.25)	158.59	71.89
10	Other Comprehensive Income				
	a) Items that will not be reclassified to profit and loss (Net of Tax)				
	- Remeasurements of the defined benefit plans : (Losses)/ Gains		2.17	-	2.17
11	Total comprehensive income for the period	169.90	(466.08)	158.59	74.06
12	Paid up Equity Share Capital (Face Value of Rs. 10/-)	1,209.42	1,071.92	1,059.62	1,071.92
13	Other equity				3,212.02
14	Earning Per Share (For continuing operations based on Weighted Average) -in INR (Not Annualised)				
	Basic	1.48	(4.37)	1.50	0.67
	Diluted	1.38	(4.17)	1.41	0.64

Mumbai
Date : 14/08/2024



FOR VAISHALI PHARMA LTD.

Atul K. V.
DIRECTOR

Registered Office :
706-709, 7th Floor, Aravali Business Center, R.C. Patel Road, Off. Sodawala Lane, Borivali (W), Mumbai-400092



Vaishali Pharma Ltd.

Notes :

1. The above financial results for the quarter ended June 30, 2024 were reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on August 14, 2023.
2. The above unaudited financial result is subject to Limited Review Report as furnished by the Statutory Auditors and approved by the Board of Directors of the Company as received under regulation 33 of SEBI (LODR) Regulation 2015.
3. The paidup equity share capital has increased to ₹ 1209.42 Lakhs (1,20,94,213 equity shares of face value ₹ 10 each) upon allotment of 13,75,000 equity shares of face value ₹ 10 each, after conversion of 13,75,000 Share warrants into 13,75,000 equity shares of face value ₹ 10 each.
4. Figures of previous reporting periods have been regrouped / reclassified wherever necessary to correspond with the figures of the current reporting period.
5. The Company has one segment of activity viz., Sale of pharmaceutical products.

By the order of Board of Directors
For Vaishali Pharma Limited


Atul Arvind Vasani
DIN : 02107085
Managing Director



Mumbai
August 14, 2023

Registered Office :

706-709, 7th Floor, Aravali Business Center, R.C. Patel Road, Off. Sodawala Lane, Borivali (W), Mumbai-400092